Sanofi Aventis

Welcome to the 'Sanofi-Aventis' tag page at Technorati. This page features content from the farthest reaches of the Blogosphere that authors have "tagged" with 'Sanofi-Aventis'.

Latest blogosphere posts tagged “Sanofi Aventis”

• Burrill Report: Biotech Innovation Gets the Cash

  
  OneMedPlace — Authority: 123
  By Marie Daghlian, The Burrill Report If the past week is any indication, big pharma is showing that it is willing to pay for biotech innovation. On the receiving end this week, Alder Biopharmaceuticals stands to reap more than $1 billion from collaboration with Bristol-Myers Squibb for the development and ...
  6 hours ago

• The inside story on bones – microsite

  
  AdPharm Blog — Authority: 146
  Microsite Print ad Click on the thumbnails to the ads on AdPharm Description: Interactive Microsite in flash showing clickable keywords positioned in the shape of a bone with layers of information depending on the keywords clicked. At the bottom of the page are three images representing a normal bone, a ...
  13 hours ago

• (GSK) GlaxoSmithKline plc Has Their H1N1 Vaccine Approved

  
  Stock Blog Hub — Authority: 461
  GlaxoSmithKline plc ( GSK ) recently received approval from the U.S. Food and Drug Administration (FDA) for its unadjuvanted influenza A (H1N1) pandemic vaccine.  The FDA approved the supplemental biologics license application (sBLA), which was filed as a strain change supplement to Glaxo’s FluLaval seasonal flu ...
  1 day ago

• FDA chief defends H1N1 vaccine supply

  
  Survival News Network — Authority: 144
  The head of the U.S. Food and Drug Administration defended the agency’s decision not to use an additive that could have stretched swine flu vaccine supplies, adding that doses should be coming more regularly.The vaccine to prevent the H1N1 strain of influenza has been in short supply following production issues but ...
  2 days ago

• FDA chief defends H1N1 vaccine supply

  
  Get Out of Dodge! — Authority: 137
  The head of the U.S. Food and Drug Administration defended the agency’s decision not to use an additive that could have stretched swine flu vaccine supplies, adding that doses should be coming more regularly. The vaccine to prevent the H1N1 strain of influenza has been in short supply following production issues ...
  2 days ago

• Sanofi’s Viehbacher Hunts For Brains In Boston

  
  Pharmalot — Authority: 596
  The Sanofi-Aventis ceo made the equivalent of a sales pitch yesterday to some 200 guests in Cambridge, Ma., yesterday in a bid to attract what he called partners for innovation. The notion is nothing new in big pharma, where drugmakers are turning over rocks to find new compounds to exploit. But Chris Viehbacher ...
  4 days ago

• Pharmalot… Pharmalittle… Good Morning

  
  Pharmalot — Authority: 596
  Nice to see you again. A few gloomy clouds are hovering over the Pharmalot corporate campus this morning, but our spirits are relatively sunny. And why not? Every brand new day should be unwrapped like a precious gift, the Morning Mayor would say. So untie your own ribbon and grab a cup of something stimulating as you ...
  4 days ago

• Sanofi Taps Biotech Firm to Bolster Its Pipeline

  
  DealBook — Authority: 775
  Increasing its bet on biotechnology, Sanofi-Aventis said it would pay an additional $1 billion over eight years to Regeneron Pharmaceuticals for the discovery of new drugs.
  4 days ago

• Sanofi Taps Biotech Firm to Bolster Its Pipeline

  
  NYT > Theater — Authority: 913
  The drugs being developed are monoclonal antibodies, which are engineered versions of proteins naturally made by the immune system.
  4 days ago

• Right Brains Wanted: Sanofi-Aventis Wants to Tap the Creative Genius of Boston-Area Biotechs

  
  Xconomy — Authority: 710
  Life Sciences , Drug Development , biotechnology Ryan McBride wrote: Sanofi-Aventis (NYSE: SNY ) hosted a large event at its R&D site in Cambridge, MA, yesterday to make its pitch for why Boston-area biotech companies should want to form partnerships with the French drug giant. It was an ...
  5 days ago

• Former Pfizer R&D Chief Joins PureTech Ventures as Senior Partner

  
  Xconomy — Authority: 710
  pharma , Life Sciences , VC Ryan McBride wrote: PureTech Ventures says it has swelled its ranks with another Big Pharma veteran. John LaMattina, former president of global research and development at Pfizer, has joined the Boston-based venture firm as senior partner. PureTech has also promoted previous ...
  6 days ago

• (RX) Big Pharma and Biotech – Industry Outlook

  
  Stock Blog Hub — Authority: 461
  The pharmaceutical industry has witnessed major changes in 2009. Performance has been affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent ...
  6 days ago

• (MITI) Micromet Misses Estimates

  
  Stock Blog Hub — Authority: 461
  Micromet ’s ( MITI ) third-quarter loss per share came in at 22 cents, well below the Zacks Consensus Estimate of 14 cents and a loss of 15 cents in the prior-year period. The company reported revenues of $4 million, compared to $7 million in the third quarter of 2008. Micromet records revenues primarily in the form ...
  6 days ago

• Up And Down The Ladder… Job Changes

  
  Pharmalot — Authority: 596
  Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us and we’ll share with it others. That’s right. Send us your announcements and we’ll find a home for them . Don’t be shy. Everyone wants to know who is coming and going, especially with all the ...
  1 week ago

• Multaq Launch Ad

  
  AdPharm Blog — Authority: 146
  Click here to see it on AdPharm AdPharm is the largest online pharmaceutical advertising gallery. It is subscription-based with various subscriptions plans available here .
  1 week ago

• Pharmalot… Pharmalittle… Morning Edition

  
  Pharmalot — Authority: 596
  Good morning, everyone. Nice to see you again. The sun is shining here on the Pharmalot corporate campus and we are busy bundling short people off to the school house. And like you, we will be focused on meetings and what-not, but will keep an eye out for interesting items to pass along. Here, in fact, are a few ...
  1 week ago

• Connecticut Attorney Gen’l Probes Vaccine Makers

  
  Pharmalot — Authority: 596
  The state is investigating complaints of price fixing and preferential treatment in the distribution of seasonal flu vaccine. Attorney General Richard Blumenthal’s office told reporters it has written to 13 manufacturers and distributors of seasonal flu vaccine, requesting details on price, supply levels and ...
  1 week ago

• Dendreon Files Provenge Application to FDA Ahead of Schedule, Now It’s Time to Wait

  
  Xconomy — Authority: 710
  Biotech , cancer , Drugs Luke Timmerman wrote: Seattle-based Dendreon said today it has completed all the necessary paperwork for its lead drug candidate, and handed over the amended application for approval to the FDA. The company had told investors to expect this milestone by “mid-November,” ...
  1 week ago

• Millions Die Due To High Prices For Malaria Drugs

  
  Pharmalot — Authority: 596
  Nearly a million people die from malaria each year because they can’t afford the most effective treatment and instead often buy old drugs to which the malaria parasite has become resistant, according to a study of six high-risk nations by Populations Services International Malaria , Reuters writes. Artemisinin ...
  1 week ago

• Micromet Signs $477M Deal with Sanofi-Aventis

  
  OneMedPlace — Authority: 123
  Micromet has licensed one of its cancer-fighting antibody candidates to Sanofi-Aventis  in a $477 million deal. Bethesda, Maryland-based Micromet will receive $12 million in cash up front for licensing an antibody that uses the company’s BiTE technology, which uses the patient’s own T-cells to fight ...
  2 weeks ago

Comments about Sanofi Aventis